Volume 13 Supplement 1
Micafungin for the treatment of pediatric invasive fungal infections
© Arrieta et al; licensee BioMed Central Ltd. 2009
Published: 13 March 2009
Pediatric patients in the ICU are highly vulnerable to invasive fungal infections ; Candida has been reported to be the third most common pathogen in pediatric ICU wards . However, information on new antifungal therapies in children remains limited. Micafungin (MICA) is a once-daily antifungal agent of the echinocandin class.
A retrospective review of MICA pediatric data from six trials.
MICA is a safe and efficacious agent for the treatment and prophylaxis of pediatric invasive fungal infections in the ICU setting.
This article is published under license to BioMed Central Ltd.